Journals / Turkish Neurosurgery / 2020 / Cilt: 30 - Sayı: 2

The Vasorelaxant and Neuroprotective Effects of Mildronate in A Rabbit Subarachnoid Hemorrhage Model

Pages
163–170
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition, the hippocampal cell degeneration score was significantly lower in themildronate group than in the SAH and vehicle groups.CONCLUSION: These results show that mildronate exerts protective effects against SAH-induced vasospasm and secondaryneural injury.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: To investigate the effects of an anti-ischemic agent, mildronate, on subarachnoid hemorrhage-induced vasospasm.MATERIAL and METHODS: Rabbits were randomly divided into four groups: control, subarachnoid hemorrhage (SAH), vehicle,and mildronate (n=8 animals per group).
📊
Key Findings & Data:In the treatment group, 200 mg/kg of mildronate were intraperitoneally administered5 minutes after the procedure and continued for 3 days as daily administrations of the same dose.
💡
Conclusion & Impact:In addition, the hippocampal cell degeneration score was significantly lower in themildronate group than in the SAH and vehicle groups.CONCLUSION: These results show that mildronate exerts protective effects against SAH-induced vasospasm and secondaryneural injury.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

AIM: To investigate the effects of an anti-ischemic agent, mildronate, on subarachnoid hemorrhage-induced vasospasm.MATERIAL and METHODS: Rabbits were randomly divided into four groups: control, subarachnoid hemorrhage (SAH), vehicle,and mildronate (n=8 animals per group). In the treatment group, 200 mg/kg of mildronate were intraperitoneally administered5 minutes after the procedure and continued for 3 days as daily administrations of the same dose. At the end of the third day,the cerebrum, cerebellum, and brain stem were perfused, fixated, and removed for histopathological examination. Tissues wereexamined for arterial wall thickness, luminal area, and hippocampal neuronal degeneration.RESULTS: Mildronate group showed significantly increased luminal area and reduced wall thickness of the basilar artery comparedwith the subarachnoid hemorrhage group. In addition, the hippocampal cell degeneration score was significantly lower in themildronate group than in the SAH and vehicle groups.CONCLUSION: These results show that mildronate exerts protective effects against SAH-induced vasospasm and secondaryneural injury.

🔖

Cite This Article

ESER, M. T., BEKTASOGLU, P. K., GÜRER, B., BOZKURT, H., SORAR, M., OZTURK, O. C., ARIKOK, A. T., KERTMEN, H. (2020). The Vasorelaxant and Neuroprotective Effects of Mildronate in A Rabbit Subarachnoid Hemorrhage Model. Turkish Neurosurgery, Cilt: 30 - Sayı: 2, 163–170. https://ajindex.com/articles/399189

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Athar MK, Levine JM: Treatment options for cerebral vasospasm in aneurysmal subarachnoid hemorrhage. Neurotherapeutics 9: 37-43, 2012 2. Barker FG, Heros RC: Clinical aspects of vasospasm. Neurosurg Clin N Am 1: 277-288, 1990 3. Barry C, Turner RJ, Corrigan F, Vink R: New therapeutic approaches to subarachnoid hemorrhage. Expert Opin Investig Drugs 21: 845-859, 2012 4. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, Hoh BL, Kirkness CJ, Naidech AM, Ogilvy CS, Patel AB, Thompson BG, Vespa P
  2. American Heart Association Stroke Council
  3. Council on Cardiovascular Radiology and Intervention
  4. Council on Cardiovascular Nursing
  5. Council on Cardiovascular Surgery and Anesthesia
  6. Council on Clinical Cardiology: Guidelines for the management of aneurysmal subarachnoid hemorrhage: A guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke 43: 1711-1737, 2012 5. Cuthbert KD, Dyck JR: Malonyl-CoA decarboxylase is a major regulator of myocardial fatty acid oxidation. Curr Hypertens Rep 7: 407-411, 2005 6. Dambrova M, Liepinsh E, Kalvinsh I: Mildronate: Cardioprotective action through carnitine-lowering effect. Trends Cardiovasc Med 12: 275-279, 2002 7. Dankbaar JW, Rijsdijk M, van der Schaaf IC, Velthuis BK, Wermer MJ, Rinkel GJ: Relationship between vasospasm, cerebral perfusion, and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Neuroradiology 51: 813-819, 2009 8. Dzintare M, Baumane L, Meirena D, Lauberte L, Kalvinsh I, Sjakste N: Involvement of nitric oxide production in the mildronate mechanism of action. Pharmacol Rev Commun 12: 163-170, 2002 9. Enina G: Medicinal effects and indications to mildronate application in neuroangiologic practice. Eksp Klin Farmakoter (Riga) 19: 163-170, 1991 10. Ergil J, Kertmen H, Sayin M, Gurer B, Yılmaz ER, Ozkan D, Arikok AT, Kanat MA, Sekerci Z: Vasoconstrictive effects of levobupivacaine on the basilar artery in the rabbit. Arch Med Sci 11: 654-659, 2015 11. Grasso G, Alafaci C, Macdonald RL: Management of aneurysmal subarachnoid hemorrhage: State of the art and future perspectives. Surg Neurol Int 8: 11, 2017 12. Grasso G, Buemi M, Giambartino F: The role of erythropoietin in aneurysmal subarachnoid haemorrhage: From bench to bedside. Acta Neurochir 120: 75-80, 2015 13. Gurer B, Turkoglu E, Kertmen H, Karavelioglu E, Arikok AT, Sekerci Z: Attenuation of cerebral vasospasm and secondary injury by testosterone following exp